Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.

The role of oestrogens in the development of prostate cancer is poorly understood. However, a large body of evidence has suggested that oestrogenic hormones may be involved in prostatic malignancy. The localization of oestrogen receptor beta (ERbeta) in the secretory epithelium of the human prostate has raised the intriguing possibility that the action of oestrogen could be mediated, at least in part, by this receptor during the process of carcinogenesis. Hence, specific interference with oestrogen-activated and ERbeta-mediated transcriptional activity could open new issues in the endocrine manipulation of prostate tumours. In the present study, we provide new insights into the role of ERbeta in the context of an androgen-responsive prostate cancer cell line such as LNCaP, which was used as a model system together with steroid receptor negative HeLa cells. ERbeta and the mutated androgen receptor (AR) T877A did not discriminate between oestrogen- or androgen-induced transactivation, whereas ERbeta and AR transcriptional activity were inhibited only by the respective hormone antagonists ICI 182,780 and casodex. Furthermore, the nuclear localization of ERbeta evaluated by immunocytochemistry confirmed the promiscuous response to hormones in addition to the specific inhibitory action of antagonists. Interestingly, ICI 182,780 and an ERbeta antisense expression vector repressed the growth effects of both 17beta-oestradiol and 5alpha-dihydrotestosterone, suggesting that ERbeta has a key role in the proliferation induced by these steroids in LNCaP prostate cancer cells. Thus our findings implicate ERbeta as a potential target for the treatment of prostate tumours.

[1]  L. Thompson,et al.  Ligand-Induced Regulation of ERα and ERβ is Indicative of Human Breast Cancer Cell Proliferation , 2003, Breast Cancer Research and Treatment.

[2]  A. Bilancio,et al.  Sex steroid hormones act as growth factors , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  S. Andò,et al.  The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. , 2002, Molecular pharmacology.

[4]  Seong-Jin Kim,et al.  Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. , 2002, Cancer research.

[5]  N. Ing,et al.  Estradiol up-regulates estrogen receptor messenger ribonucleic acid in endometrial carcinoma (Ishikawa) cells by stabilizing the message. , 2002, Journal of molecular endocrinology.

[6]  Seong-Jin Kim,et al.  Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. , 2002, Cancer research.

[7]  V. Speirs,et al.  Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue , 2002, The Journal of pathology.

[8]  S. Andò,et al.  Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. , 2001, Molecular pharmacology.

[9]  S. Ho,et al.  Clinical review 134: The endocrinology of prostate cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[10]  J. Gustafsson,et al.  Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer , 2001 .

[11]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[12]  L. Andersson,et al.  A role for estrogen receptor β in the regulation of growth of the ventral prostate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  V. Njar,et al.  Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  A. Bilancio,et al.  Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.

[16]  L. Pinsky,et al.  Interactions between androgen and estrogen receptors and the effects on their transactivational properties , 2000, Molecular and Cellular Endocrinology.

[17]  J. Gustafsson,et al.  Functional Differences between the Amino-Terminal Domains of Estrogen Receptors α and β , 2000 .

[18]  S. Ho,et al.  Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. , 2000, Cancer research.

[19]  A. Jazaeri,et al.  Selective loss of estrogen receptor β in malignant human colon , 2000 .

[20]  S. Andò,et al.  Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. , 1999, Cancer research.

[21]  H. Bonkhoff,et al.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. , 1999, The American journal of pathology.

[22]  B. Katzenellenbogen,et al.  Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). , 1998, Endocrinology.

[23]  S. Yeh,et al.  From estrogen to androgen receptor: a new pathway for sex hormones in prostate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Katzenellenbogen,et al.  Determinants of Ligand Specificity of Estrogen Receptor-α: Estrogen versus Androgen Discrimination* , 1998, The Journal of Biological Chemistry.

[25]  P. Wingo,et al.  An adjustment to the 1997 estimate for new prostate cancer cases , 1997, Cancer.

[26]  K. Korach,et al.  Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse. , 1997, Endocrinology.

[27]  A. Maggi,et al.  Oligonucleotide squelching reveals the mechanism of estrogen receptor autologous down-regulation. , 1997, Molecular endocrinology.

[28]  W. Pratt,et al.  Steroid receptor interactions with heat shock protein and immunophilin chaperones. , 1997, Endocrine reviews.

[29]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[30]  N. Copeland,et al.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. , 1997, Molecular endocrinology.

[31]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[32]  E. Wilson,et al.  Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. , 1996, Urology.

[33]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[36]  Miguel Beato,et al.  Transcriptional regulation by steroid hormones , 1996, Steroids.

[37]  H. Sasano,et al.  Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma , 1996, Histopathology.

[38]  O. Lukkarinen,et al.  Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. , 1995, The Journal of clinical endocrinology and metabolism.

[39]  T. Deguchi,et al.  Expression of estrogen receptor in diseased human prostate assessed by non‐radioactive in situ hybridization and immunohistochemistry , 1995, The Prostate.

[40]  G. Carruba,et al.  Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. , 1995, Endocrinology.

[41]  F. S. French,et al.  Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. , 1995, Molecular endocrinology.

[42]  A. Levine,et al.  Estrogen receptor messenger RNA expression in human benign prostatic hyperplasia: detection, localization, and modulation with a long-acting gonadotropin-releasing hormone agonist. , 1994, Journal of andrology.

[43]  W. Catalona,et al.  Management of cancer of the prostate. , 1994, The New England journal of medicine.

[44]  G. Carruba,et al.  Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. , 1994, Cancer research.

[45]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[46]  N. Sato,et al.  Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  M. Garnick,et al.  Prostate Cancer: Screening, Diagnosis, and Management , 1993, Annals of Internal Medicine.

[48]  A. Levine,et al.  Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. , 1991, The Journal of urology.

[49]  Jean D. Wilson,et al.  Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells , 1991, Molecular and Cellular Endocrinology.

[50]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[51]  M. Beato.  Gene regulation by steroid hormones , 1989, Cell.

[52]  P. Chambon,et al.  Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[54]  G. Pinkus,et al.  Multiple phenotypes of prostatic glandular cells in castrated dogs after individual or combined treatment with androgen and estrogen. Morphometric, ultrastructural, and cytochemical distinctions. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[55]  William E. Paterson,et al.  Federal Republic of Germany , 1985, International Journal of Comparative Labour Law and Industrial Relations.

[56]  B. Neubauer,et al.  Actions of estrogen in the male. , 1979, Investigative urology.

[57]  I. Leav,et al.  Bipotentiality of response to sex hormones by the prostate of castrated or hypophysectomized dogs. Direct effects of estrogen. , 1978, The American journal of pathology.

[58]  H. Klocker,et al.  Androgen signal transduction and prostatic carcinoma , 2004, World Journal of Urology.

[59]  G. Prins,et al.  Estrogen Receptor-b Messenger Ribonucleic Acid Ontogeny in the Prostate of Normal and Neonatally Estrogenized Rats , 1998 .

[60]  I. Leav,et al.  Rat Estrogen Receptor-α and -β, and Progesterone Receptor mRNA Expression in Various Prostatic Lobes and Microdissected Normal and Dysplastic Epithelial Tissues of the Noble Rats. , 1998, Endocrinology.

[61]  K. Grandien,et al.  Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors a and b , 1997 .

[62]  M. Webber,et al.  Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications part 2. Tumorigenic cell lines , 1997, The Prostate.

[63]  A. Brinkmann,et al.  Androgens, antiandrogens and androgen receptor abnormalities. , 1996, European urology.

[64]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[65]  L. Skoog,et al.  Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue , 1992, The Prostate.

[66]  H. Schulze,et al.  Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry , 1990, The Prostate.

[67]  P. Leedman,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells* , 2022 .

[68]  Eva Enmark,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Human Estrogen Receptor �-Gene Structure, Chromosomal Localization, and Expression Pattern* , 2022 .